Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma with Dr Matthew Matasar

Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma.

CME information and select publications here